European regulators accept Teva and Medincell’s application for long-acting Schizophrenia injection
Share
Teva Pharmaceutical Industries (NYSE:TEVA) and Medincell announced Thursday that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, an investigational long-acting injectable formulation designed to treat adults living with schizophrenia.
